Previous 10 | Next 10 |
Pryor will spearhead BeiGene’s efforts to pair global health equity with diversity and inclusion BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health ...
2023-03-21 11:18:17 ET Wells Fargo said that Zymeworks ( NASDAQ: ZYME ) is a buy citing the biotech's potential royalty streams and milestones from its lead oncology candidate. The firm has a $12 price target (~41% upside based on Monday's close). Derek Archila wrote t...
Company Hits Construction Milestone for Flagship Manufacturing and R&D Facility in Hopewell BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last...
BeiGene press release ( NASDAQ: BGNE ): Q4 GAAP EPADS of -$4.29 misses by $0.10 . Revenue of $380.1M (+77.6% Y/Y) misses by $8.07M . Cash, Cash Equivalents, Restricted Cash and Short-Term Investments were $4.5 billion as of December 31, 2022, compared to $6.6 billion a...
Recorded product revenue of $339.0 million and $1.3 billion for the fourth quarter and full year, respectively, increasing 72.3% and 97.9% from the prior-year periods BRUKINSA ® product revenue totaled $176.1 million and $564.7 million for the quarter and full year, respectiv...
Summary Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront and up to $1.1 billion in milestones. The $937 million agreement between Beijing InnoCare and Biog...
BeiGene ( NASDAQ: BGNE ) is scheduled to announce Q4 earnings results on Monday, February 27th, before market open. The consensus EPS Estimate is -$4.18 and the consensus Revenue Estimate is $388.17M (+81.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revi...
NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the China Nation...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in Cowen’s 43 rd Annual Healthcare Conference on Monday, March 6 th , 2023 with a fireside chat at 11:10 am ET. Live webcasts of these events ...
Summary Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response. Zanidatamab is now Jazz's responsibility and Zymeworks stands to benefit as the program moves forward. Wit...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...